Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies (ASCEND-LYM)

  • End date
    Aug 31, 2025
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 2 May 2022


ASCEND-LYM is a prospective, multi-center, observational study aimed at detecting early stage lymphoma and constrcuting prognostic model by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 493 participants including lymphoid malignancies and benign diseases.

Condition Lymphoma
Treatment early detection test
Clinical Study IdentifierNCT05275036
SponsorSun Yat-sen University
Last Modified on2 May 2022


Yes No Not Sure

Inclusion Criteria

Age 40-75 years at the day of consenting to the study
Able to provide a written informed consent
Additional Inclusion Criteria for Cancer Participants
No prior cancer treatment (local or systematic) prior to blood draw
High suspicious or pathologically confirmed lymphoid malignancies within 42 days prior to blood draw
Additional Inclusion Criteria for Benign Disease Participants
No prior radical treatment of the benign diseases prior to study blood draw
Pathologically confirmed diagnosis of lymphoid benign diseases within 90 days prior to blood draw

Exclusion Criteria

Insufficient qualified blood samples
During pregnancy or lactation
Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
Recipient of blood transfusion within 7 days prior to blood draw
Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw, such as rheumatic drugs (methotrexate, cyclophosphamide, or azathioprine), or endocrine drugs (tamoxifen)
Additional Exclusion Criteria for Cancer Participants
With other known malignant tumors or multiple primary tumors
Lymphoid malignancies unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw
Additional Exclusion Criteria for Benign Disease Participants
With other known malignant tumors or comfirmed lymphoid malignancies
Lymphoid benign diseases unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note